Ewing's sarcoma: Prognostic factors, disease control, and the reemerging role of surgical treatment

M. I. O'Connor, D. J. Pritchard

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Advances in the treatment of Ewing's sarcoma have been dramatic. Present treatment protocols control local disease by radiotherapy, surgery, or both; systemic spread is limited by aggressive multiagent chemotherapy. In patients with localized osseous Ewing's sarcoma, five-year survival rates now range from 54% to an estimated 74%. With late relapse not uncommon, control of the primary lesion is critical to long-term survival. Several studies now show improved local control and possibly improved survival of patients with surgical treatment of primary osseous Ewing's sarcoma.

Original languageEnglish (US)
Pages (from-to)78-87
Number of pages10
JournalClinical Orthopaedics and Related Research
Issue number262
StatePublished - 1991

Fingerprint

Ewing's Sarcoma
Survival
Clinical Protocols
Radiotherapy
Therapeutics
Survival Rate
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Cite this

Ewing's sarcoma : Prognostic factors, disease control, and the reemerging role of surgical treatment. / O'Connor, M. I.; Pritchard, D. J.

In: Clinical Orthopaedics and Related Research, No. 262, 1991, p. 78-87.

Research output: Contribution to journalArticle

@article{50fb03bed83949c4bde59d4e8d84b271,
title = "Ewing's sarcoma: Prognostic factors, disease control, and the reemerging role of surgical treatment",
abstract = "Advances in the treatment of Ewing's sarcoma have been dramatic. Present treatment protocols control local disease by radiotherapy, surgery, or both; systemic spread is limited by aggressive multiagent chemotherapy. In patients with localized osseous Ewing's sarcoma, five-year survival rates now range from 54{\%} to an estimated 74{\%}. With late relapse not uncommon, control of the primary lesion is critical to long-term survival. Several studies now show improved local control and possibly improved survival of patients with surgical treatment of primary osseous Ewing's sarcoma.",
author = "O'Connor, {M. I.} and Pritchard, {D. J.}",
year = "1991",
language = "English (US)",
pages = "78--87",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "262",

}

TY - JOUR

T1 - Ewing's sarcoma

T2 - Prognostic factors, disease control, and the reemerging role of surgical treatment

AU - O'Connor, M. I.

AU - Pritchard, D. J.

PY - 1991

Y1 - 1991

N2 - Advances in the treatment of Ewing's sarcoma have been dramatic. Present treatment protocols control local disease by radiotherapy, surgery, or both; systemic spread is limited by aggressive multiagent chemotherapy. In patients with localized osseous Ewing's sarcoma, five-year survival rates now range from 54% to an estimated 74%. With late relapse not uncommon, control of the primary lesion is critical to long-term survival. Several studies now show improved local control and possibly improved survival of patients with surgical treatment of primary osseous Ewing's sarcoma.

AB - Advances in the treatment of Ewing's sarcoma have been dramatic. Present treatment protocols control local disease by radiotherapy, surgery, or both; systemic spread is limited by aggressive multiagent chemotherapy. In patients with localized osseous Ewing's sarcoma, five-year survival rates now range from 54% to an estimated 74%. With late relapse not uncommon, control of the primary lesion is critical to long-term survival. Several studies now show improved local control and possibly improved survival of patients with surgical treatment of primary osseous Ewing's sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0025968086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025968086&partnerID=8YFLogxK

M3 - Article

C2 - 1984935

AN - SCOPUS:0025968086

SP - 78

EP - 87

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 262

ER -